** Rare disease diagnostics company GeneDx WGS.O shares up ~8.9% at $92.8
** Piper Sandler initiates coverage on WGS with "overweight" rating, saying the company has a unique first-mover advantage in a fast-growing and expanding market in rare disease testing
** WGS has high penetration rates among key clinician types, including an 80% market share among genetics experts and 13% among pediatric neurologists - brokerage
** Piper Sandler sets PT at $110, implying a ~29% upside to stock's last close
** Six of seven brokerages rate the stock "buy" or higher, one "hold"; median PT is $105 - data compiled by LSEG
** Including session's moves, stock up ~20.8% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。